eXmoor Pharma and Signadori Bio have entered into a partnership aimed at advancing a gene-modified monocyte-derived macrophage cell therapy programme for solid tumours.
The collaboration agreement will see eXmoor, an integrated cell and gene therapy contract development and manufacturing organisation, support Signadori in the transition from discovery through to good manufacturing practice (GMP)-compliant manufacturing of its lead candidate.
eXmoor will carry out a technology translation and development programme at its cell and gene therapy centre, as well as provide a Head of Chemistry, Manufacturing and Controls to join Signadori’s leadership team on an interim basis.
Signadori is currently advancing a platform designed to overcome the barriers associated with treating solid cancers, developed at the Gustave Roussy Institute.
Though financial details of the alliance have not been disclosed, the partners said they will operate under a shared decision-making framework that “[aligns] scientific, technical and commercial planning with Signadori Bio’s investment trajectory”.
eXmoor’s Chief Executive Officer, Angela Osborne, said: “We are delighted to partner with Signadori Bio on such a promising and sophisticated cell therapy programme. Their approach to targeting solid tumours with gene-modified monocytes is innovative and well-grounded in translational science.”
Matthieu Coutet, Chief Executive Officer of Signadori Bio and Partner at Sofinnova Partners, added: “Partnering with eXmoor is a decisive step in our mission to bring next-generation monocyte-based therapies to patients with solid tumours. Their… expertise in early-stage process development and GMP translation is exactly what we need at this critical inflection point.”
